Biotechnology - Regeneron

Filter

Current filters:

Regeneron

Popular Filters

1 to 25 of 36 results

Bayer/Regeneron’s Eylea approved in Japan for DME

18-11-2014

German pharma major Bayer’s Japanese subsidiary, Bayer Yakuhin, has received approval from the Ministry…

BayerBiotechnologyEyleaJapanOphthalmicsRegeneronRegulation

Regeneron third-qtr net profit plunges despite strong sales growth

Regeneron third-qtr net profit plunges despite strong sales growth

04-11-2014

US biotech firm Regeneron posted revenue of $725.8 million for the third quarter of 2014, a rise of 22%…

alirocumabBayerBiotechnologydupilumabEyleaFinancialOphthalmicsRegeneronResearchSanofisarilumab

Eylea drives Regeneron’s 2nd-qtr to beat expectations

Eylea drives Regeneron’s 2nd-qtr to beat expectations

05-08-2014

USA-based biotech company Regeneron (Nasdaq: REGN) revealed today that total revenues for the second…

BiotechnologyBusiness FinanceEyleaFinancialOphthalmicsRegeneronUSA

Regeneron’s Eylea gains FDA approval for DME

Regeneron’s Eylea gains FDA approval for DME

30-07-2014

The Food and Drug Administration has approved US biotech firm Regeneron Pharmaceuticals’ Eylea (aflibercept)…

BayerBiotechnologyEyleaOphthalmicsRegeneronRegulationUSA

EULAR: Positive Ph III sarilumab data in RA from Sanofi and Regeneron

EULAR: Positive Ph III sarilumab data in RA from Sanofi and Regeneron

12-06-2014

French drug major Sanofi and partner US biotech firm Regeneron Pharmaceuticals have presented positive…

Anti-Arthritics/RheumaticsBiotechnologyRegeneronResearchSanofisarilumab

Regeneron revenues leap, boosted by stronger than expected sales of Eylea

Regeneron revenues leap, boosted by stronger than expected sales of Eylea

11-02-2014

US biotech firm Regeneron Pharmaceuticals reports that its blockbuster ophthalmic drug Eylea (aflibercept)…

BayerBiotechnologyEyleaFinancialOncologyOphthalmicsRegeneronResearchSanofiZaltrap

Positive two-year Ph III VISTA trial of Eylea in DME

Positive two-year Ph III VISTA trial of Eylea in DME

10-02-2014

US biotech firm Regeneron Pharmaceuticals and partner Germany’s Bayer have released positive results…

BayerBiotechnologyEyleaOphthalmicsRegeneronResearch

Regeneron and Bayer expand deal to develop new option for wet-AMD

Regeneron and Bayer expand deal to develop new option for wet-AMD

14-01-2014

US biotech firm Regeneron Pharmaceuticals said yesterday that it has expanded its accord with German…

BayerBiotechnologyEyleaLicensingOphthalmicsRegeneronResearch

Regeneron amends investor agreement with Sanofi

Regeneron amends investor agreement with Sanofi

13-01-2014

US biotech firm Regeneron Pharmaceuticals says it has amended and restated its investor agreement with…

BiotechnologyMergers & AcquisitionsRegeneronSanofi

Drug approvals for Bayer in USA and Japan

Drug approvals for Bayer in USA and Japan

23-11-2013

There were two pieces of good news for German Pharma and chemicals major Bayer on Friday (November 22),…

AmgenAsia-PacificBayerBiotechnologyEyleaNexavarNorth AmericaOncologyOnyx PharmaceuticalsOphthalmicsPharmaceuticalRegeneronRegulation

Regeneron 3rd-qtr beats expectations, as total revenues leap 40%

Regeneron 3rd-qtr beats expectations, as total revenues leap 40%

06-11-2013

US biotech firm Regeneron Pharmaceuticals has posted financial and operating results for the third quarter…

BayerBiotechnologyEyleaFinancialOphthalmicsRegeneron

Sanofi’s alirocumab monotherapy reduced LDL cholesterol three times more than ezetimibe

Sanofi’s alirocumab monotherapy reduced LDL cholesterol three times more than ezetimibe

16-10-2013

Sanofi and partner Regeneron Pharmaceuticals this morning released results from the Phase III ODYSSEY…

BiotechnologyCardio-vascularPharmaceuticalRegeneronResearchSanofi

Approved cancer drug potentially could help treat diabetes, Stanford researchers find

16-09-2013

A pair of studies by researchers at the Stanford University School of Medicine has identified a molecular…

afliberceptBayerBiotechnologyDiabetesEyleaOncologyPharmaceuticalRegeneronResearchSanofiZaltrap

Regeneron revenues leap on Eylea progress

06-08-2013

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) saw its shares fall 4% to $260 in pre-market…

BayerBiotechnologyEyleaFinancialRegeneron

Eylea meets primary endpoint in Ph III DME study

06-08-2013

German pharma major Bayer (BAYN: DE) revealed this morning (August 6) that, in the Phase III VIVID-DME…

BayerBiotechnologyEyleaOphthalmicsPharmaceuticalRegeneronResearch

Positive Ph III results for Regeneron/Bayer's Eylea in mCNV

06-06-2013

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) and partner Germany's Bayer (BAYN: DE) have…

BayerBiotechnologyEyleaOphthalmicsPharmaceuticalRegeneronResearch

Avastin remains preferred DME therapy, despite Lucentis extended label in USA

30-05-2013

Despite the approval of Swiss drug major Roche (ROG: SIX) subsidiary Genentech's Lucentis (ranibizumab…

AvastinBayerBiotechnologyEyleaGenentechLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneronRoche

Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations

22-05-2013

French drug major Sanofi (Euronext: SAN) and US biotech partner Regeneron Pharmaceuticals (Nasdaq: REGN)…

BiotechnologydupilumabPharmaceuticalRegeneronResearchRespiratory and PulmonarySanofi

Regeneron acquires rights to two ophthalmology programs from Sanofi

03-05-2013

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) has expanded its ophthalmology portfolio by…

BiotechnologyEyleaFinancialLicensingOphthalmicsPharmaceuticalRegeneronSanofi

1 to 25 of 36 results

Back to top